They Are Poisoning Americans (And Getting Away With It)

The federal court’s ruling in 2022 examined how the EPA handled the evidence. The court noted that the EPA’s own scientists wrote a cancer review concluding they could reach no conclusion about glyphosate’s link to non-Hodgkin lymphoma, yet the agency’s final document stamped it “not likely” to cause cancer—a contradiction the court called unsupported. The EPA has published guidelines for evaluating carcinogenicity, but the court found the agency disregarded animal studies showing tumors and dismissed the more toxic formulations like Roundup (as opposed to pure glyphosate). Skin absorption—a major route for farmers—was also ignored. The court used words like “arbitrary,” “inconsistent reasoning,” and “divorced from its own guidelines.” It ordered the EPA to redo the review. As of 2026, the speaker states no cancer warning has been added, and exposure continues. The ruling is rarely discussed in mainstream media and directly challenges the regulatory status quo.

The speaker walks through documented cases: Jess Rowland, deputy division director at EPA’s Office of Pesticide Programs, told Monsanto’s regulatory affairs manager about blocking another agency’s glyphosate investigation and later became a consultant for Monsanto associates after retiring. Marion Copely, a 30-year EPA toxicologist dying of breast cancer, wrote Rowland a letter listing 14 mechanisms by which glyphosate causes tumors, pleading with him to “do the right thing” and not base decisions on his bonus; she died in 2014 and Rowland continued chairing the committee that cleared glyphosate. Linda Fisher moved from EPA pesticides chief to Monsanto VP of government affairs, then back to EPA deputy administrator. Mary Manny Bussen, former EPA toxicologist, was texted by Monsanto to block a glyphosate review and replied, “Sweetheart, I know lots of people. You can count on me,” later returning as EPA division director. Court documents revealed Monsanto employees drafted safety studies published under independent researchers’ names, including a key 2000 study. Michael Taylor, a Monsanto attorney, became FDA deputy commissioner of policy shaping GM food regulation, returned to Monsanto as VP, then went back to the FDA as senior adviser. The speaker frames this as a systemic failure where protectors work for the company selling the product.

The speaker emphasizes that the four replacement ingredients—diquat dibromide, fluazifop-P-butyl, triclopyr, and imazapic—are not safer. He specifically targets diquat dibromide, describing it as 200 times more chronically toxic than glyphosate, classified as a highly hazardous pesticide, banned in the EU and China, and 45 times more toxic to human health based on the new formulation. It damages intestines, kills beneficial gut bacteria, interferes with nutrient absorption, triggers chronic inflammation, and is more toxic to bees, birds, fish, and earthworms, with greater leaching into groundwater. Critically, the packaging looks nearly identical to the old glyphosate-based product, with no language alerting consumers to the higher risks. This, the speaker argues, is a bait-and-switch that leaves the public unprotected and unaware.